The cardiovascular benefits of regular physical exercise are well established. 1 However, a small proportion of young (≤35 years) athletes with unsuspected heart disease are at increased risk of exercise related sudden cardiac death. 2 The majority of such deaths are attributable to cardiac anomalies, [2] [3] [4] most of which can be identified during life. A range of therapeutic strategies can be implemented to prevent fatalities, raising support for screening young athletes in medical and sporting communities. [5] [6] [7] [8] [9] The efficacy, cost effectiveness, and impact of false positive tests of preparticipation screening strategies are, however, controversial. This article provides a factual overview of preparticipation screening, as more general practitioners are likely to be confronted with the questions relating to cardiovascular screening in athletes in countries where systematic screening programmes are currently not available.
Epidemiology and demographics of sudden cardiac death in young athletes
Sudden cardiac death in young athletes is uncommon. In the United States a retrospective review of 650 000 competitive high school athletes aged 15-17 reported an incidence of 0.5 per 100 000 per year. 10 In Italy, a prospective population based observational study reported the higher incidence of 2.1 per 100 000 per year in athletes aged . 2 The absence of systematic registries precludes data relating to the incidence of sudden cardiac death in young athletes in most other European countries.
Over 90% of sudden cardiac deaths in young athletes occur during or shortly after exercise. 2 A sex and sport related predilection exists, with a predominance in males (male to female ratio 9:1) and the largest number of deaths reported in soccer and basketball. Higher participation rates provide the most plausible explanation. The mean age of sudden cardiac death in young athletes ranges from 17.1 to 23. 2 3 A broad spectrum of congenital, inherited, and acquired cardiovascular diseases causes sudden cardiac death (fig 1) . Inherited cardiomyopathies are the commonest cause, with hypertrophic cardiomyopathy accounting for over one third of cases of sudden cardiac deaths in athletes in the United States 5 and arrhythmogenic right ventricular cardiomyopathy predominating in Italy. 4 Congenital coronary artery anomalies and premature atherosclerosis account for almost 20% of cases of sudden cardiac death. 4 What is the objective of preparticipation screening? The potential for preventing sudden cardiac death in young athletes by abstinence from exercise of moderate to high intensity, pharmacotherapy, or implantation of a cardiovertor defibrillator has prompted the medical and sporting community to recommend preparticipation cardiovascular screening to permit identification of potentially fatal disorders. Both the American Heart Association and the European Society of Cardiology agree that the justifications for providing preparticipation screening to protect athletes are compelling. 5 6 Given the low prevalence of the disorders implicated in sudden cardiac death during sport, several thousand athletes would need to be screened to identify a small number at risk, therefore the emphasis is on providing the most cost effective method for minimising sudden cardiac death. What are the current practices? Most countries do not offer systematic programmes for preparticipation screening. In the United States the American Heart Association recommends such screening using a health questionnaire and physical examination (box 1). 5 This strategy seems cheap and easy to carry out but has limited value as 80% of athletes who die as a result of sudden cardiac death are asymptomatic and physical examination identifies few implicated disorders. The lack of sensitivity of the American model was highlighted in a series of 115 reported cases of sudden cardiac deaths in young athletes who had been screened. A correct diagnosis was identified in only one athlete (0.9%), who was allowed to compete. The limited sensitivity of this strategy has been further highlighted by prospective observational studies in the United Kingdom and Italy. 12 13 In Italy a unique state sponsored, national preparticipation screening programme has been in operation for over 25 years. The programme, which evaluates several million athletes annually, comprises a history, examination, and electrocardiography. Athletes with abnormalities on initial evaluation are investigated further and those with potentially serious abnormalities are disqualified (fig 2) . 13 14 The additional electrocardiography increases the sensitivity of the programme, enabling the diagnosis of a large proportion of cardiomyopathies and disorders of accessory pathways and ion channels. Although the definitive diagnosis of cardiomyopathies depends on cardiac imaging, electrocardiographic abnormalities are exhibited by 95% of people with hypertrophic cardiomyopathy and 80% of those with arrhythmogenic right ventricular cardiomyopathy. 15 16 Is the Italian model effective in identifying cardiovascular disorders in young athletes? The efficacy of the Italian screening programme in the identification of cardiomyopathies is established. Evidence suggests, however, that the strategy is not effective in detecting athletes with congenital coronary anomalies or premature coronary atherosclerosis. 17 In a large population based study of screening outcomes in 33 735 young athletes in the Veneto region of Italy, 621 (1.8%) were disqualified because of an identified cardiovascular disorder. Of these, 22 (0.07%) were considered to have hypertrophic cardiomyopathy, predominantly (73%) on the basis of an abnormal electrocardiogram. 13 This frequency is similar to that observed in a population based study in the United States, which used echocardiography, suggesting that the Italian model performs as well as echocardiography in detecting hypertrophic cardio myopathy. 18 The specificity of the Italian programme in excluding the diagnosis of hypertrophic cardiomyopathy was also assessed in a study of 4450 elite athletes who were initially judged eligible for
Sources and selection criteria
We searched PubMed and Medline from 1980 onwards using the search terms "preparticipation screening", "sudden death", "electrocardiogram", "athletes", "black athletes", and "cost-effectiveness". Although we scrutinised and selected the highest quality articles, comprising original papers, reviews, recommendations, and consensus reports, the studies are all population based, prospective or retrospective observational reports. To our knowledge the efficacy of preparticipation screening programmes in young athletes has not been subjected to controlled trials, as they would be challenging to do both ethically and technically.
Box 1 American Heart Association guidelines for preparticipation cardiovascular screening of young, competitive athletes Medical history* Chest pain or discomfort on exertion Unexplained syncope or near syncope † Excessive exertional dyspnoea or fatigue Prior recognition of a heart murmur Raised systemic blood pressure
Family history
Premature death (<50 years) from heart disease, in one or more relatives Disability from heart disease in a close relative aged less than 50
Specific knowledge of certain cardiac conditions in family members: hypertrophic and dilated cardiomyopathy, long QT syndrome or other ion channelopathies, Marfan's syndrome, or clinically important arrhythmias
Physical examination
Heart murmur ‡ Femoral pulses to exclude aortic coarctation Physical stigmata of Marfan's syndrome Brachial artery blood pressure (sitting position, taken in both arms) *Parental verification is recommended for high school and middle school athletes †Judged not to be vasovagal; of particular concern when related to exertion ‡Auscultation should be done both while supine and while standing or with Valsalva manoeuvre, specifically to identify murmurs of dynamic left ventricular outflow tract obstruction with permission of the European Society of Cardiology competition after preparticipation screening using 12 lead electrocardiography. The athletes underwent echocardiography to assess previously undetected hypertrophic cardiomyopathy. 19 After an average follow-up of eight years hypertrophic cardiomyopathy was diagnosed in only one (0.02%) athlete indicating that a normal electrocardiogram has a high negative predictive value (99.98%), excluding hypertrophic cardiomyopathy in most athletes. More recent experience from the Italian programme suggests that screening using 12 lead electrocardiography is also effective in detecting athletes with arrhythmogenic right ventricular cardiomyopathy. 17 Does the Italian model reduce the number of sudden cardiac deaths in young athletes? Although hypertrophic cardiomyopathy is the commonest cause of exercise related sudden cardiac death in the United States, in Italy it is responsible for a much smaller proportion of deaths. Although antagonists of preparticipation screening argue that this might reflect a lower genetic cluster of people with hypertrophic cardiomyopathy in the Mediterranean region, these figures probably reflect the efficacy of the Italian programme in identifying athletes with hypertrophic cardiomyopathy and minimising deaths through disqualification from sport; none of the 22 athletes identified with hypertrophic cardiomyopathy in the Veneto region between 1979 and 1996 died during a mean follow-up of 8.2 years. Of the 49 deaths recorded among young athletes during the same period, only one had hypertrophic cardiomyopathy (2%)-lower than the incidence of 7.3% recorded in 220 sudden deaths among non-athletes. 13 The most compelling evidence for the Italian preparticipation screening model reducing the incidence of sudden cardiac death in sport is derived from a subsequent prospective study by the same group. The group compared the incidence of sudden cardiac death between the prescreening era and a 25 year period of screening and showed a reduction in incidence of sudden cardiac death from 3.6 per 100 000 person years before screening to 0.4 per 100 000 person years in 2003-4 (fig 3) . 17 These figures represent a 90% reduction in mortality since preparticipation screening was implemented and predominantly result from fewer cases of sudden cardiac death from cardiomyopathies, particularly arrhythmogenic right ventricular Years Sudden death per 100 000 athlete years 1 9 7 9 -8 0 1 9 8 1 -2 1 9 8 3 -4 1 9 8 5 -6 1 9 8 7 -8 1 9 8 9 -9 0 1 9 9 1 -2 1 9 9 3 -4 1 9 9 5 -6 1 9 9 7 -8 1 9 9 9 -2 0 0 0 2 0 0 1 -2 cardiomyopathy-a relatively novel entity in the early screening era which cardiologists have become more effective at diagnosing. Of concern, however, was the unchanged incidence of sudden cardiac death from coronary disorders.
What are the limitations of 12 lead electrocardiography as a screening tool? Electrocardiography is unable to identify premature coronary artery disease and congenital coronary anomalies, which account for a major proportion of sudden cardiac death in young athletes. 4 17 Testing might also fail to detect people with long QT syndrome and arrhythmogenic right ventricular cardiomyopathy with incomplete phenotypic expression.
Electrocardiographic changes associated with physical conditioning often overlap with those observed in cardiomyopathy, resulting in unnecessary investigations or false disqualification of athletes. Therefore preparticipation screening should be done by cardiologists with knowledge of cardiovascular adaptation to exercise as well as the broad phenotypic manifestations of the cardiomyopathies. Even in the most experienced hands, the false positive rate may be unacceptably high. An observational study of 1005 selected Italian athletes reported an incidence for mildly or distinctly abnormal electrocardiogram findings of 40%, only 5% of which were eventually diagnosed as a cardiovascular abnormality. The investigators reported an electrocardiographic sensitivity of 51%, specificity of 61%, positive predictive value of 7%, and negative predictive value of 96%, raising concerns about the value of such testing in preparticipation screening. 20 A large Italian study of 42 386 young athletes screened over 22 years and using more conventional electrocardiographic criteria (box 2) found a false positive rate of 7%, with only 2% of athletes being disqualified because of cardiovascular disease. 4 The impact of ethnicity on cardiovascular adaptation in athletes has not been studied in detail; however, evidence is emerging that noticeable repolarisation changes, similar to those observed in people with cardiomyopathies, are more commonly exhibited by Afro-Caribbean athletes. Further data relating to the spectrum of physiological electrocardiographic changes in this cohort are required. 21 22 What is the psychological impact of preparticipation screening?
No data have been published on the psychological impact of preparticipation screening in young athletes. On the basis of studies on established screening programmes 23 24 it is reasonable to assume that athletes with a false positive test result will be anxious until further investigations can provide reassurance. The psychological burden is even greater in young athletes with a diagnosis of a potentially life threatening condition and who are excluded from competing. This highlights the need for prompt evaluation of athletes who fail the initial screening, as well as the need for expert psychological support if preparticipation screening in athletes is to be adopted. Few data exist on the cost effectiveness of preparticipation screening in young athletes, and these are not easily comparable. The American model is cheap but relatively ineffective. A cost effectiveness analysis of a prospective observational study of 5615 high school athletes in the United States, which compared history with electrocardiographic examination (assuming that 10% of the athletes identified as being at risk would live an additional 40 years and 90% an additional 20 years), showed that electrocardiography was more cost effective than history and electrocardiographic examination combined, costing $44 000 (£24 897; €30 921) per year of life saved compared with $84 000 per year of life saved. 25 26 An Italian cost effectiveness analysis of 33 735 athletes compared the screening cost of the Italian model with that of the American model. Using a more conservative approach (10% of affected athletes would live an additional 20 years) the study estimated the cost per year of life saved at €14 220 for the Italian model and €37 750 for the American model. 27 These estimates were in the context of a well organised, national setting where preparticipation cardiovascular screening was part of a wider screening programme. In countries such as the United Kingdom, however, where the health service is already burdened by limited finances and resources, the implementation of a national screening programme to identify silent cardiac diseases in athletes cannot be regarded as cost effective.
Does preparticipation screening comply with the World Health Organization screening criteria? Critics highlight that preparticipation screening does not fulfil most of the WHO criteria (box 3). Although sudden cardiac deaths of athletes may be regarded as an important health problem by some, it is uncommon and is caused by rare disorders, the clinical course of which are not always fully understood. Deaths are the result of diverse diseases and therefore no single investigation can identify all disorders capable of causing sudden cardiac death. Moreover, most countries have limited facilities for the diagnosis and treatment of athletes. Finally, even the most optimistic estimates, as reported by the Italian group, suggest that the cost of preparticipation cardiovascular screening exceeds that of established screening programmes for breast and cervical cancer. 29 Conversely, evidence suggests that electrocardiography is a suitable and acceptable screening test (simple, safe, precise, and validated) for the identification of the cardiomyopathies and cardiac conduction tissue diseases. A long latent stage is also recognised as well as effective intervention for improved outcomes.
Conclusion
Preparticipation cardiovascular screening of young competitive athletes is recommended by both the American Heart Association and the European Society of Cardiology. 5 6 The European recommendations have been endorsed by the International Olympic Committee and the football governing bodies, with the Union of European Football Associations advocating mandatory screening of all players participating in European championships. 7 9 These recommendations are based on Italy's experience of preparticipation screening for 25 years, which has shown that screening is effective in reducing sudden cardiac death from cardiomyopathies at the expense of some false positive test results. Implementation of preparticipation screening is hampered in most countries by lack of expertise, Ongoing research and unanswered questions Ongoing research Electrocardiographic and echocardiographic characteristics of athletes of Afro-Caribbean origin to identify the spectrum of electrocardiographic changes and the upper limits of physiological left ventricular hypertrophy in this cohort to facilitate the differentiation between athlete's heart and cardiomyopathy Charity funded prospective evaluation of a large cohort of British athletes to identify the prevalence of disorders capable of causing sudden cardiac death in athletes to support arguments for or against preparticipation screening in the United Kingdom Molecular genetics of cardiomyopathies and ion channel diseases to facilitate early diagnosis of these disorders in the future
Unanswered questions
What is the precise significance of noticeable repolarisation changes, specifically deep T wave inversions in the presence of a structurally normal heart?
What is the precise false negative rate of electrocardiographic screening in different ethnic groups and can the same criteria of electrocardiographic abnormality that warrants further investigation be used for all athletes?
Tips for non-specialists Symptoms, clinical signs, and electrocardiographic abnormalities of significant importance that should raise concern about young athletes and initiate a referral to a specialist are:
Chest pain or discomfort on exertion Unexplained syncope or near syncope during exertion Dyspnoea that is disproportional to the amount of exercise being performed Palpitations associated with any of the above A family history of hereditary cardiac disorder or sudden cardiac death in a first degree relative when young (≤40 years)
Marfanoid phenotype
Left parasternal, systolic heart murmur that increases in intensity when standing or with Valsalva manoeuvre Electrocardiographic abnormalities (see box 2) Athletes with clinical symptoms and signs of an infection-for example, flu-like symptoms, should be advised against intense exercise until they have made a complete recovery owing to the risk of myocarditis resources, and infrastructure. Concerns are also justified that further research is required on the efficacy and cost effectiveness of preparticipation screening. The studies from Italy, however, provide the best available evidence to date, supporting the implementation of systematic preparticipation screening for the prevention of sudden cardiac death in young athletes. Although such programmes are effective at minimising deaths from cardiomyopathies and cardiac conduction tissue disorders, they have no impact on deaths from coronary anomalies or premature coronary atherosclerosis.
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